◼ Archived
Business
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
Alkermes reports positive Phase Ib trial data for ALKS 7290, sparking significant market and medical interest.
Alkermes
1 trends tracked about this subject — the full history, oldest to newest below.